{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T15:06:44Z","timestamp":1782832004357,"version":"3.54.5"},"reference-count":17,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["dldjournalonline.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.dld.2016.08.113","type":"journal-article","created":{"date-parts":[[2016,8,23]],"date-time":"2016-08-23T04:12:55Z","timestamp":1471925575000},"page":"1394-1397","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["High rate of hepatitis B viral breakthrough in elderly non-Hodgkin lymphomas patients treated with Rituximab based chemotherapy"],"prefix":"10.1016","volume":"48","author":[{"given":"Roberto","family":"Castelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurenzia","family":"Ferraris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Pantaleo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Lambertenghi Deliliers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Cicardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2016.08.113_bib0005","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/1096-9071(200011)62:3<299::AID-JMV1>3.0.CO;2-0","article-title":"Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors","volume":"62","author":"Yeo","year":"2000","journal-title":"Journal of Medical Virology"},{"key":"10.1016\/j.dld.2016.08.113_bib0010","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1038\/sj.bjc.6601699","article-title":"Comprehensive analysis of risk factors associating with hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy","volume":"90","author":"Yeo","year":"2004","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.dld.2016.08.113_bib0015","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1177\/1756283X12450245","article-title":"Management of hepatitis B reactivation in patients receiving cancer chemotherapy","volume":"5","author":"Huang","year":"2012","journal-title":"Therapeutic Advances in Gastroenterology"},{"key":"10.1016\/j.dld.2016.08.113_bib0020","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/0016-5085(91)90599-G","article-title":"Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study","volume":"100","author":"Lok","year":"1991","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2016.08.113_bib0025","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1053\/j.gastro.2014.10.038","article-title":"American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy","volume":"148","author":"Perrillo","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2016.08.113_bib0030","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.dld.2006.12.017","article-title":"Prophylaxis and treatment of hepatitis B in immunocompromised patients","volume":"39","author":"Marzano","year":"2007","journal-title":"Digestive and Liver Disease"},{"issue":"Suppl. 1","key":"10.1016\/j.dld.2016.08.113_bib0035","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/S1590-8658(10)60692-5","article-title":"HBV disease: HBsAg carrier and occult B infection reactivation in haematological setting","volume":"43","author":"Marinone","year":"2011","journal-title":"Digestive and Liver Disease"},{"key":"10.1016\/j.dld.2016.08.113_bib0040","doi-asserted-by":"crossref","first-page":"e0134315","DOI":"10.1371\/journal.pone.0134315","article-title":"Correction: chronic hepatitis B virus infection: the relation between hepatitis B antigen expression, telomere length, senescence, inflammation and fibrosis","volume":"10","author":"Tachtatzis","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.dld.2016.08.113_bib0045","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jhep.2006.10.007","article-title":"Occult hepatitis B virus infection","volume":"46","author":"Raimondo","year":"2007","journal-title":"Journal of Hepatology"},{"issue":"Suppl. 1","key":"10.1016\/j.dld.2016.08.113_bib0050","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S1386-6532(05)00384-7","article-title":"Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention","volume":"34","author":"Lavanchy","year":"2005","journal-title":"Journal of Clinical Virology"},{"key":"10.1016\/j.dld.2016.08.113_bib0055","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1053\/gast.2001.22461","article-title":"Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease","volume":"120","author":"Perrillo","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2016.08.113_bib0060","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.dld.2016.08.113_bib0065","doi-asserted-by":"crossref","first-page":"951","DOI":"10.3324\/haematol.12557","article-title":"Hepatitis B virus-related liver disease in isolated anti-hepatitis B-core positive lymphoma patients receiving chemo- or chemo-immune therapy","volume":"93","author":"Targhetta","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.dld.2016.08.113_bib0070","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1517\/14712598.2014.912273","article-title":"Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy","volume":"14","author":"Vigan\u00f2","year":"2014","journal-title":"Expert Opinion on Biological Therapy"},{"key":"10.1016\/j.dld.2016.08.113_bib0075","doi-asserted-by":"crossref","DOI":"10.1007\/s15010-016-0891-1","article-title":"Occult HBV infection in the oncohematological setting","author":"Sagnelli","year":"2016","journal-title":"Infection"},{"key":"10.1016\/j.dld.2016.08.113_bib0080","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/apt.13036","article-title":"Differences in nephrotoxicity risk and renal effects among anti-viral therapies against hepatitis B","volume":"41","author":"Koklu","year":"2015","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1016\/j.dld.2016.08.113_bib0085","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1001\/jama.2014.15704","article-title":"Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial","volume":"312","author":"Huang","year":"2014","journal-title":"JAMA"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865816306909?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865816306909?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,8]],"date-time":"2018-09-08T22:53:17Z","timestamp":1536447197000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865816306909"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":17,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["S1590865816306909"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2016.08.113","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High rate of hepatitis B viral breakthrough in elderly non-Hodgkin lymphomas patients treated with Rituximab based chemotherapy","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2016.08.113","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}